VIRACEPT- nelfinavir mesylate tablet, film coated USA - engelsk - NLM (National Library of Medicine)

viracept- nelfinavir mesylate tablet, film coated

pd-rx pharmaceuticals, inc. - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir 250 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection. coadministration of viracept is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in table 3 ]. coadministration of viracept is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in table 3 [also see drug interactions (7), table 6 ]. pregnancy category b viracept should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there are no adequate and well-controlled studies in pregnant women taki

VIRACEPT- nelfinavir mesylate tablet, film coated USA - engelsk - NLM (National Library of Medicine)

viracept- nelfinavir mesylate tablet, film coated

state of florida doh central pharmacy - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir mesylate 625 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv infection. in the clinical studies described below, efficacy was evaluated by the percent of patients with plasma hiv rna < 400 copies/ml (studies 511 and 542) or < 500 copies/ml (study actg 364), using the roche rt-pcr (amplicor) hiv-1 monitor or < 50 copies/ml, using the roche hiv-1 ultrasensitive assay (study avanti 3). in the analysis presented in each figure, patients who terminated the study early for any reason, switched therapy due to inadequate efficacy or who had a missing hiv-rna measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have hiv-rna above 400 copies/ml, above 500 copies/ml, or above 50 copies/ml at subsequent time points, depending on the assay that was used. study 511 was a double-blind, randomized, placebo controlled trial comparing treatment with zidovudine (zdv; 200 mg tid) and lamivudine (3tc; 150 mg bid) plus 2 doses

VIRACEPT- nelfinavir mesylate tablet, film coated USA - engelsk - NLM (National Library of Medicine)

viracept- nelfinavir mesylate tablet, film coated

h.j. harkins company, inc. - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir 250 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv infection. in the clinical studies described below, efficacy was evaluated by the percent of patients with plasma hiv rna < 400 copies/ml (studies 511 and 542) or < 500 copies/ml (study actg 364), using the roche rt-pcr (amplicor) hiv-1 monitor or < 50 copies/ml, using the roche hiv-1 ultrasensitive assay (study avanti 3). in the analysis presented in each figure, patients who terminated the study early for any reason, switched therapy due to inadequate efficacy or who had a missing hiv-rna measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have hiv-rna above 400 copies/ml, above 500 copies/ml, or above 50 copies/ml at subsequent time points, depending on the assay that was used. study 511 was a double-blind, randomized, placebo-controlled trial comparing treatment with zidovudine (zdv; 200 mg tid) and lamivudine (3tc; 150 mg bid) plus 2 doses

VIRACEPT- nelfinavir mesylate tablet, film coated USA - engelsk - NLM (National Library of Medicine)

viracept- nelfinavir mesylate tablet, film coated

agouron - nelfinavir mesylate (unii: 98d603vp8v) (nelfinavir - unii:ho3ogh5d7i) - nelfinavir 250 mg - viracept in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection. coadministration of viracept is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of nelfinavir) are listed in table 3 [also see drug interactions (7), table 6 ]. alpha 1-adrenoreceptor antagonist alfuzosin potentially increased alfuzosin concentrations can result in hypotension. antiarrhythmics amiodarone, quinidine potential for serious and/or life-threatening cardiac arrhythmia. antimycobacterial agents rifampin plasma concentrations of nelfinavir can be reduced by concomitant use of rifampin. this may lead to loss of therapeutic effect and possible development of resistance to viracept or other coadministered antiretroviral agents. antipsychotics ergot derivatives dihydroergotamine, ergotamin

Viracept Den europeiske union - maltesisk - EMA (European Medicines Agency)

viracept

roche registration ltd. - nelfinavir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - viracept huwa indikat fit-trattament ta 'kombinazzjoni antiretrovirali ta' adulti, adolexxenti u tfal ta 'tlett snin u ikbar li huma infettati bil-virus tal-bniedem-immunodefiċjenza (hiv-1). fl-protease inhibitor (pi) pazjenti b'esperjenza, l-għażla ta ' nelfinavir għandha tkun ibbażata fuq testijiet tar-reżistenza virali u l-istorja tat-trattament.

Viracept Den europeiske union - latvisk - EMA (European Medicines Agency)

viracept

roche registration ltd. - nelfinavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - viracept ir indicēts antiretrovīrusu zāļu kombinētajai ārstēšanai ar cilvēka imūndeficīta vīrusa (hiv-1) inficētiem pieaugušajiem, pusaudžiem un bērniem no 3 gadu vecuma. jo proteāze-inhibitori (pi)-pieredzējuši pacientiem, izvēle nelfinavir būtu balstīta uz individuāliem vīrusu rezistences pārbaudes un apstrādes vēsture.

VIRACEPT -250MG Comprimé Canada - fransk - Health Canada

viracept -250mg comprimé

pfizer canada ulc - nelfinavir (mésylate de nelfinavir) - comprimé - 250mg - nelfinavir (mésylate de nelfinavir) 250mg - hiv protease inhibitors

VIRACEPT -50MG Poudre Canada - fransk - Health Canada

viracept -50mg poudre

pfizer canada ulc - nelfinavir (mésylate de nelfinavir) - poudre - 50mg - nelfinavir (mésylate de nelfinavir) 50mg - hiv protease inhibitors

VIRACEPT Comprimé Canada - fransk - Health Canada

viracept comprimé

pfizer canada ulc - nelfinavir (mésylate de nelfinavir) - comprimé - 625mg - nelfinavir (mésylate de nelfinavir) 625mg - hiv protease inhibitors

VIRACEPT -250MG TABLET Canada - engelsk - Health Canada

viracept -250mg tablet

pfizer canada ulc - nelfinavir (nelfinavir mesylate) - tablet - 250mg - nelfinavir (nelfinavir mesylate) 250mg - hiv protease inhibitors